1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

 
• By Joseph Haas

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

Although Alnylam Pharmaceuticals Inc.'s recent safety crisis with Phase III candidate revusiran suggests that RNA interference therapies remain a long way from the market, RXi Pharmaceuticals Corp. thinks it has a unique approach with a shorter, self-delivering form of RNAi therapeutic that can solve the delivery issue safely and get ideal penetration into targeted areas in dermatology and ophthalmology.

In an interview with Scrip, RXi's CEO Geert Cauwenbergh, formerly CEO of New Jersey dermatology specialty firm Barrier Therapeutics Inc., said his company went into those two therapeutic areas to maximize limited funds for clinical trials, though the self-delivering RNAi approach could be applicable in a much broader range of indications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.